Observational studyCancer medicine2026
Multigene Germline Panel Testing in Gastric Cancer Patients in a Portuguese Population.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07387237 (Multigene Germline Panel Testing in Gastric Cancer Patients in Portugal), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multigene Germline Panel Testing in Gastric Cancer Patients in Portugal
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer is a heterogeneous disease with both environmental and genetic determinants. While Multigene Germline Panel Testing (MGPT) increasingly reveals hereditary predisposition, the prevalence and clinical significance of germline variants in Portuguese gastric cancer patients tested through institutional MGPT programs remain insufficiently characterised. The main objective of this study was to determine the prevalence and spectrum of germline pathogenic variants and likely pathogenic variants in gastric cancer patients from Portugal, and to explore their clinicopathological correlations.
methodsWe conducted a pilot retrospective observational study including 51 patients with histologically confirmed gastric cancer who underwent MGPT between 2020 and 2025. Genetic testing was performed using validated 15 or 30 gene panels. Clinical, pathological, and survival data were retrieved from medical records.
resultsGermline pathogenic or likely pathogenic variants were detected in 6 patients (11.8%), involving MLH1, MSH6, PMS2, CHEK2, and BLM. Variants of uncertain significance (VUS) were identified in 11.8%. No CDH1 alterations were observed. Compared with MGPT-negative cases, MGPT-positive patients were significantly younger at diagnosis (median 48 vs. 76 years, p = 0.00) and more frequently presented with mixed-type gastric cancer (33.3% vs. 4.4%, p = 0.05). No significant associations were found with tumour stage or treatment.
conclusionsIn this Portuguese cohort, nearly 12% of consecutive real-world MGPT-tested gastric cancer patients had germline pathogenic or likely pathogenic variants, predominantly in mismatch repair genes but also in CHEK2 and BLM. These findings further illustrate the heterogeneity of hereditary gastric cancer beyond classical CDH1 mutations and support the integration of MGPT into clinical care to identify at-risk individuals not captured by current criteria. Larger multicentre studies are warranted to validate these results and clarify the role of emerging susceptibility genes.
trial registrationStudy Registration Number: NCT07387237.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.